When is an incremental innovation not an incremental innovation?

Posted by:

The UK government recently announced that it would be offering all toddlers the flu vaccine as a nasal spray rather than as the traditional injection. All children aged two will be offered vaccination against flu, with the UK becoming the first country to offer the vaccine to healthy children free of charge. The new immunisation programme aims to give annual protection to 650,000 two-year-olds using a nasal spray called Fluenz.

As a mother, I was delighted to hear this news. As ...

Continue Reading →
0

Debate on clinical trials and data transparency raises series of unanswered question for EMA

Posted by:

Yesterday lunchtime at the Brussels campus of Maastricht University, Pugatch Consilium was pleased to host a roundtable discussion and launch its latest report on ‘Clinical trials and data transparency – the Public Interest case’. Around the table were representatives from the academic community, patient groups, industry, scientists, pharmacists, doctors and policymakers, who debated the policy issues along with the 3 authors of the report.

Professor Meir Pugatch, Haifa University and Founder of Pugatch Consilium, opened the proceedings by summarising the key ...

Continue Reading →
0

Pugatch Consilium Launches New Paper on Clinical Trials

Posted by:

Pugatch Consilium launches new paper on Clinical trials and data transparency examining the public interest case for more pro-active release of clinical trials data and asking whether the benefits to public welfare are outweighed by the hurdles of bureaucracy, patient privacy and concerns over protection of IPRs and commercial confidentiality. Download a copy from the Research & Analysis Reports page.

Continue Reading →
0

Clinical trials and data transparency – The public interest case

Posted by:

On Monday 16 September 2013, Pugatch Consilium will be hosting a  joint workshop with Maastricht University and launching a new briefing paper on Clinical Trials and Data Transparency – the Public Interest Case.

The European Medicines Agency (EMA) is now consulting on a new policy for a more transparent, open and pro-active system to promote the public release of clinical trials data. The level of transparency, whether it is voluntary or compulsory, and the extent to which such regulations ...

Continue Reading →
0

The Cronut Recipe, Half Croissant + Half Doughnut = Full Trademark Protection?

Posted by:

Pugatch Consilium’s Jacques Johann Stemmet dives into the pudgy minefield of intellectual property rights and baked goods.

 

The Cronut: Carefully laminated croissant-like dough, delicately fried in grapeseed oil at the perfect temperature, then rolled in sugar, crammed with cream and topped with a glossy glaze. Of course Dominique Ansel has not shared all his tricks to the recipe, but he has informed us of his secret ingredient, trademark protection. This does not mean Ansel can now relax and watch the dough ...

Continue Reading →
0

India – the odd man out

Posted by:

Last week, Pugatch Consilium released a new report on India showing the country is still an outlier when it comes to innovation and protection of IPRs. Dr David Torstensson, Senior Consultant and author of the report, discussed and debated its findings at a workshop in Washington DC organised by the Global Intellectual Property Center of the US Chamber of Commerce.

To view the webcast:

http://www.uschamber.com/webcasts/india-international-outlier-ip

To read the report in full:

http://www.pugatch-consilium.com/?page_id=113

Image: Courtesy of Ian Wagreich, U.S. Chamber of Commerce

Continue Reading →
0
Page 8 of 15 «...678910...»